Nogapendekin alfa inbakicept clinical trials
Also written N-803, ALT-803 and Anktiva.
Its developmentBy ImmunityBio, step by step45 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses nogapendekin alfa inbakicept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nogapendekin alfa inbakicept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Apr 2024 · ANKTIVA · BLA 761336 (FDA, Drugs@FDA)
- European Union
- 16 Feb 2026 · Anktiva · EMEA/H/C/006622 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
77 studies that test it; most in 2017 (17); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 17 |
| 2018 | 14 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 45 · Other 33
ImmunityBio, Inc. (39) · National Cancer Institute (NCI) (10) · Washington University School of Medicine (5) · Altor BioScience (5) · Masonic Cancer Center, University of Minnesota (5) · University of Minnesota (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Thai Red Cross AIDS Research Centre (1)
Often tested with
Tested in the same studies.
ETBX-011 (17) · ETBX-061 (17) · GI-4000 (16) · ETBX-051 (16) · GI-6301 (16) · Yeast-CEA vaccine (12) · ETBX-021 (8) · Albumin-Bound Paclitaxel (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6
Studies that test nogapendekin alfa inbakicept.
- Nov 2026Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerPhase 2 · ImmunityBio, Inc.
- Dec 2026Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaPhase 2 · National Cancer Institute (NCI)
- Dec 2026Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerPhase 1/2 · National Cancer Institute (NCI)
- Dec 2026PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCPhase 2 · Dana-Farber Cancer Institute
- Mar 2027A Study to Examine Anktiva for the Treatment of COVID-19.Phase 2 · ImmunityBio, Inc.
- Oct 2027Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)Phase 1/2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses nogapendekin alfa inbakicept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 78
- Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillanceRecruitingPhase 2National Cancer Institute (NCI)NCT07574541Written as N-803
- NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With SepsisNot yet recruitingPhase 2ImmunityBio, Inc.NCT07783789Written as Nogapendekin alfa inbakicept (NAI)
- Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT06149481Written as N-803
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT06253494Written as N-803
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyRecruitingPhase 3ImmunityBio, Inc.NCT06745908Written as N-803
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT06239220Written as NAI
- IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07686380Written as N-803
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingPhase 1ImmunityBio, Inc.NCT07217496Written as Nogapendekin Alfa Inbakicept (NAI)
- A Study to Examine Anktiva for the Treatment of COVID-19.RecruitingPhase 2ImmunityBio, Inc.NCT07123727Written as Anktiva
- Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT06161545Written as N-803
- N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular TherapyRecruitingEarly Phase 1Seth PollackNCT07261657Written as Nogapendekin Alfa Inbakicept
- Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerNot yet recruitingPhase 1Washington University School of MedicineNCT07756593Written as N803
- A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaRecruitingPhase 2St. Jude Children's Research HospitalNCT07085338Written as N803
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingPhase 1/2Washington University School of MedicineNCT07355205Written as Nogapendekin alfa inbakicept
- Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNot yet recruitingPhase 2ImmunityBio, Inc.NCT07628062Written as Nogapendekin Alfa Inbakicept (NAI)
- A Study to Assess Anktiva in Patients With Long Covid-19.RecruitingPhase 2ImmunityBio, Inc.NCT07108036Written as N-803 (IL-15 Superagonist)
- Interleukin-15 to Promote Post-ART Control of HIVEnrolling by invitationPhase 2Michael Peluso, MDNCT07145164Written as N-803
- Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingPhase 2ImmunityBio, Inc.NCT06829823Written as N-803 and BCG
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedPhase 1/2National Cancer Institute (NCI)NCT05642195Written as N-803
- NAI for Sepsis With Persistent LymphopeniaWithdrawnPhase 2ImmunityBio, Inc.NCT07578558Written as Nogapendekin alfa inbakicept (NAI)
See all 78 studies that test nogapendekin alfa inbakicept →
Given beside what is tested · 15 — nogapendekin alfa inbakicept is usual care or a partner of the new treatment
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerRecruitingPhase 2ImmunityBio, Inc.NCT06710288Written as N-803
- Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaRecruitingPhase 1ImmunityBio, Inc.NCT05618925Written as N803
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruitingPhase 2ImmunityBio, Inc.NCT07477366Written as N-803
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1ImmunityBio, Inc.NCT04898543Written as N-803 (Cohort 2 part B)
- CIML NK Cell in Head & Neck CancerCompletedPhase 1Dana-Farber Cancer InstituteNCT04290546Written as Interleukin-15 Superagonist (N-803)
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruitingPhase 2ImmunityBio, Inc.NCT06061809Written as N-803
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedPhase 3ImmunityBio, Inc.NCT03520686Written as Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)WithdrawnPhase 2ImmunityBio, Inc.NCT07492888Written as Nogapendekin Alfa-Inbakicept (NAI)
- Immunotherapy Before and After SurgeryWithdrawnPhase 2ImmunityBio, Inc.NCT06765902Written as N-803
- Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.WithdrawnPhase 2ImmunityBio, Inc.NCT06765954Written as N-803 (IL-15 Superagonist)
- Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus InfectionCompletedPhase 1/2National Cancer Institute (NCI)NCT04247282Written as N803
- QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03563157Written as ALT-803
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesTerminatedPhase 1/2ImmunityBio, Inc.NCT04927884Written as N-803
- N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIVWithdrawnPhase 1/2University of MinnesotaNCT04144335Written as N-803 and bNAbs
- 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)WithdrawnPhase 2University of ArkansasNCT03003728Written as ALT-803
What changed recently
From the registry's own updates since Oct 19, 2026.
Started recruiting1
Stopped1
- NAI for Sepsis With Persistent LymphopeniaWithdrawnNov 17, 2026NCT07578558
Codes
What other systems call nogapendekin alfa inbakicept · ClinicalTrials.gg INT006311
- MeSH (NLM) C582303nogapendekin alfa inbakiceptConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7TK323DLA0NOGAPENDEKIN ALFA INBAKICEPTConfirmed FDA, NLM
- NCI Thesaurus C205507Nogapendekin Alfa InbakiceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582303 | nogapendekin alfa inbakicept | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7TK323DLA0 | NOGAPENDEKIN ALFA INBAKICEPT | Confirmed FDA, NLM |
| NCI Thesaurus | C205507 | Nogapendekin Alfa Inbakicept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.